Eagle Pharmaceuticals
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
- On November 9, 2023, Eagle Pharmaceuticals announced a delay in filing their financial report for the quarter ending September 30, 2023. The company cited the need for additional time to review potential adjustments related to the sales reporting of PEMFEXY® as the primary reason for this delay. Subsequently, on November 29, 2023, Eagle disclosed that its CEO, Scott Tarriff, had resigned effective immediately. The board accepted his resignation, and the separation agreement included clawback provisions. These provisions would allow the board to retrieve or annul any payments made to Tarriff if it was found that he engaged in any behavior constituting “cause” under his employment contract.As of the current date, Eagle has yet to file its Form 10-Q. Consequently, the company received a notice of deficiency from Nasdaq due to this failure. These series of events have significantly impacted Eagle’s stock, resulting in a notable decline in the share price.
On November 9, 2023, Eagle Pharmaceuticals announced a delay in filing their financial report for the quarter ending September 30, 2023. The company cited the need for additional time to review potential adjustments related to the sales reporting of PEMFEXY® as the primary reason for this delay. Subsequently, on November 29, 2023, Eagle disclosed that its CEO, Scott Tarriff, had resigned effective immediately. The board accepted his resignation, and the separation agreement included clawback provisions. These provisions would allow the board to retrieve or annul any payments made to Tarriff if it was found that he engaged in any behavior constituting “cause” under his employment contract.
As of the current date, Eagle has yet to file its Form 10-Q. Consequently, the company received a notice of deficiency from Nasdaq due to this failure. These series of events have significantly impacted Eagle’s stock, resulting in a notable decline in the share price.
